Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 with FSRT for Brain Metastases
NCT02187822Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abeotaxane in brain metastases, sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Oct 2014; status: terminated.
02
Drugs
abeotaxane
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02187822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187822.